EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›SOPH

SOPH

SOPHiA GENETICS SA

Next earnings Aug 3, 2026 · consensus $-0.23 EPS, $22.1M rev

Sell
$5.75
▲ +1.05%
$5.75▲ +86.08%
over 1Y
L $2.99EODHDH $5.75
Today+1.1%
1W+1.1%
1M+13.2%
3M+22.3%
YTD+23.1%
1Y+86.1%
OverviewValuationQualityFilings
Rating
Sell
Quality
—
Valuation
Fair value
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy

Mixed signals in the latest filings.

SOPHiA GENETICS SA shows limited reported revenue.

Financials · annual, by fiscal year

No income data filed.

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$394M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash—

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+2.7%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Recent filings

all on EDGAR ↗
144Filing2026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗4Period ending 2026-06-252026-06-26open ↗144Filing2026-06-25open ↗4Period ending 2026-06-222026-06-23open ↗4Period ending 2026-06-222026-06-23open ↗144Filing2026-06-22open ↗144Filing2026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗4Period ending 2026-06-182026-06-22open ↗

Quality score

—
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial health—
Momentum—
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals

Frequently asked

Is SOPHiA GENETICS SA (SOPH) a buy?
SOPH currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.

Sources: SEC EDGAR (CIK 0001840706, latest 144 filed 2026-06-26) · EODHD · as of 6/29/2026, 2:36:42 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 4 sales

2026-06-25
Verma Abhimanyu
Chief Technology Officer
Sell6.94K @ $5.51$38.2K
2026-06-25
Menu Philippe
Chief Medical Officer
Sell5.00K @ $5.50$27.5K
2026-06-22
CARDOZA GEORGE
Chief Financial Officer
Sell774.00 @ $5.38$4.16K
2026-06-22
Muken Ross
President
Sell422.00 @ $5.38$2.27K
2026-06-18
Cox Troy
Director
Award19.7K @ $5.46$108K
2026-06-18
HIBBS KATHY L
Director
Award19.7K @ $5.46$108K
2026-06-18
Ossipow Vincent
Director
Award19.7K @ $5.46$108K
2026-06-18
Cossery Jean-Michel
Director
Award19.7K @ $5.46$108K

Recent news

market news →
SOPHiA Genetics Closes Public Offering Of $57 Mln Of SharesBullish
nasdaq.com· 2026-06-22
SOPHiA Announces Pricing Of $50 Mln Public Offering At $4.75 Per ShareBullish
nasdaq.com· 2026-06-17
Biggest stock movers Wednesday: LZB, SPCX, and moreBullish
seekingalpha.com· 2026-06-17
SOPHiA GENETICS prices $50M public offering at $4.75 per share
seekingalpha.com· 2026-06-17
Stocks to watch on Tuesday after hours: LZB, AMCX, SOPHBullish
seekingalpha.com· 2026-06-16
SOPHiA GENETICS S.A. Q1 2026 Earnings Call SummaryBullish
finance.yahoo.com· 2026-05-05

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score— vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity— vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 4d
Neutral
+0.01
vs typical · 8 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.